BeyondSpring (BYSI) Accumulated Expenses (2015 - 2026)
BeyondSpring (BYSI) posted Accumulated Expenses of $1.3 million for Q1 2026, up 36.25% sequentially from $938000.0 in Q4 2025, and up 30.54% YoY from $979000.0 in Q1 2025.
BeyondSpring (BYSI) Accumulated Expenses (2015 - 2026) Analysis & Trends
BeyondSpring has reported Accumulated Expenses for 12 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Accumulated Expenses rose 30.54% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 30.54% YoY) and the FY2025 annual result came in at $938000.0, up 11.67% from the prior year.
- Accumulated Expenses improved to $1.3 million in Q1 2026 per BYSI's latest filing, from $938000.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $2.7 million in Q2 2022 and troughed at $840000.0 in Q4 2024.
- A 5-year average of $1.5 million and a median of $1.3 million in 2026 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2026: Accumulated Expenses sank 64.21% in 2024, then jumped 30.54% in 2026.
- Over 5 years, Accumulated Expenses stood at $2.5 million in 2022, then slipped by 4.98% to $2.3 million in 2023, then slumped by 64.21% to $840000.0 in 2024, then gained by 11.67% to $938000.0 in 2025, then soared by 36.25% to $1.3 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $1.3 million, $938000.0, and $990000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.39 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 938,000.00 |
| Sep 30, 2025 | 990,000.00 |
| Jun 30, 2025 | 926,000.00 |
| Mar 31, 2025 | 979,000.00 |
| Dec 31, 2024 | 840,000.00 |
| Jun 30, 2024 | 1.77 Mn |
| Dec 31, 2023 | 2.35 Mn |
| Jun 30, 2023 | 1.68 Mn |
| Dec 31, 2022 | 2.47 Mn |
| Jun 30, 2022 | 2.70 Mn |
| Dec 31, 2021 | 3.86 Mn |
| Sep 30, 2021 | 7.19 Mn |
| Jun 30, 2021 | 7.21 Mn |
| Mar 31, 2021 | 5.76 Mn |
| Dec 31, 2020 | 5.61 Mn |
| Sep 30, 2020 | 8.38 Mn |
| Jun 30, 2020 | 7.19 Mn |
| Mar 31, 2020 | 4.70 Mn |